Archived Insight | November 6, 2019
Our team can reduce your healthcare costs and keep your organization in good shape. We'll help you simplify and lower expenses with our holistic, comprehensive healthcare cost reduction insights.
Our deep bench of health consultants uses a wide variety of strategies to help reduce your healthcare costs, including:
Underlying and supporting all of the hard work we’ll perform for you is our cutting-edge data analytics, which allows us to find innovative solutions to your most pressing healthcare cost problems. Called SHAPE (Segal’s Health Analysis of Plan Experience), our proprietary data mining tool saved Connecticut’s state government millions in healthcare costs.
The State’s claims data showed that one regional pharmacy dispensed approximately $6 million annually in high-cost drugs from one manufacturer.
This one manufacturer accounted for almost 80% of the plan spend dispensed through this pharmacy. At another pharmacy, the one drug company’s products accounted for over 88% of the plan spend dispensed through this pharmacy.
These high utilization levels from one manufacturer raised the potential issue of “captive pharmacies,” which derive the vast majority of drug volume from one manufacturer or drug.
As part of our ongoing services to the State, Segal used our proprietary SHAPE data mining analytical tool to drill down into the State’s plan experience and utilization patterns that suggested disproportionate spend.
We convinced the State’s Pharmacy Benefit Manager (PBM), CVS/Caremark, to conduct an audit of both pharmacies over a six-month period. Although the PBM audit did not reveal discrepant claims or fraudulent activity, it also did not address the issue of excessive spend by the captive pharmacies.
The State also asked Segal to investigate other pharmaceutical manufacturers. In our review of over 30 manufacturers, we found no abuses as significant as those from the one manufacturer in question.
Because of the analysis in our SHAPE captive pharmacy report, the State implemented utilization management to limit the use of problematic drugs by the manufacturer.
CVS/Caremark is also removing the suspect regional pharmacy from its national network. These changes resulted in estimated savings to the State of almost $6 million annually.
This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.